Plain-English translation of NCT05635929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new topical composition called XCM-OM118, delivered as a gel and mouthwash, to help prevent or reduce severe mouth sores in people receiving radiation therapy for head and neck cancer. The study has two parts: one during your cancer treatment to see if the medication reduces mouth sores, and another six months after treatment ends to see if it helps with long-term quality of life issues like pain and difficulty swallowing.
Radiation therapy for head and neck cancer commonly causes painful mouth sores that can make eating, speaking, and swallowing difficult, and can even interfere with completing treatment. Even after treatment ends, patients often experience lasting problems like chronic pain and dry mouth. Researchers want to know if this new treatment can prevent these problems during and after cancer care.
You likely qualify if…
You likely don't qualify if…
During radiation treatment, you will apply the gel three times daily (before bed, mid-morning, mid-afternoon) and also before and after each therapy session. Your mouth will be checked weekly by a clinician, and you will answer questions about any mouth pain or difficulty eating or speaking. If you continue into the second part of the study six months after treatment ends, you will use the gel and mouthwash for one month and complete quality-of-life questionnaires before and after that month.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Spain